Best Options Strategy for KURA
Looking for the best options strategy for Kura Oncology, Inc. (KURA)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live KURA option chain right now, and a simple map from your view on KURA to the strategy that fits it. Model any of them in the calculator before you trade.
About KURA
Kura Oncology, Inc. (KURA) is a major company in Biotechnology. Options traders on KURA tend to watch , since these can drive large moves in the share price.
About Kura Oncology, Inc.
Kura Oncology is a biopharmaceutical company focused on developing cancer treatments. The company's flagship product, KOMZIFTI (ziftomenib), is an oral menin inhibitor that has reached commercialization. Beyond this approved medicine, Kura maintains a pipeline of experimental compounds in clinical development, including darlifarnib, which is being studied in combination with other targeted drugs across various solid tumor types, and KO-7246, a next-generation menin inhibitor being explored for both cancer applications and metabolic disorders like diabetes and cardiovascular disease. The company is based in San Diego, California.
Kura generates revenue primarily from sales of KOMZIFTI. The company's business model depends on successfully advancing its pipeline candidates through clinical trials and obtaining regulatory approval, which would enable additional revenue streams as those medicines reach the market. Success hinges on demonstrating that its experimental treatments work effectively in their respective indications and can compete in the oncology and metabolic disease markets.
Today's top-scoring strategy for KURA
Our engine ranks defined-risk strategies on the live KURA chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $7 | $0.10 |
| Sell | 1× | PUT | $11 | $2.68 |
| Sell | 1× | CALL | $10 | $0.90 |
| Buy | 1× | CALL | $10 | $0.90 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Strategy analysis
Greeks vs price
Price × volatility (today)
| −30% | −15% | IV | +15% | +30% | |
|---|---|---|---|---|---|
| $13 | $206 | $185 | $165 | $146 | $129 |
| $13 | $195 | $173 | $153 | $135 | $119 |
| $12 | $181 | $159 | $140 | $122 | $107 |
| $12 | $165 | $143 | $125 | $109 | $95 |
| $11 | $146 | $126 | $109 | $94 | $82 |
| $11 | $124 | $107 | $92 | $79 | $68 |
| $10 | $100 | $85 | $73 | $62 | $53 |
| $10 | $73 | $63 | $53 | $45 | $37 |
| $9 | $45 | $38 | $32 | $27 | $21 |
| $9 | $15 | $13 | $11 | $8 | $4 |
| $8 | −$15 | −$12 | −$12 | −$12 | −$13 |
Live scan from 2026-08-14 · quotes delayed ~15 minutes
Historical backtest: how a Iron Butterfly on KURA would have performed
We approximated a Iron Butterfly on KURA, entered repeatedly over the past year (92 historical entries, each held to expiration) with Black-Scholes-modelled entry premiums. Here is how that would have played out on real KURA price history — an educational backtest, not a prediction of future returns.
Approximate: entry premiums are modelled with Black-Scholes from trailing realised volatility, held to expiration and settled against the real historical close. Real fills, implied volatility and slippage differ — treat it as directional context, not exact returns.
Implied volatility
KURA is currently trading with high implied volatility, which makes its options expensive — and attractive to sell. On the options we scanned that was around 135% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on KURA currently price in about 135% implied volatility, versus roughly 58% the stock has actually realised over the past month. That makes options relatively expensive — an edge for strategies that sell premium, such as credit spreads and iron condors.
KURA's IV Rank is 91/100: implied volatility sits 91% of the way between its 13-day low (66%) and high (141%), and is above 79% of recorded days. Premium is historically rich, which favours net-credit strategies like credit spreads and iron condors.
Off that volatility, the options market is pricing a move of about ±$4.41 (±41%) in KURA by 2026-09-18 — a range of roughly $6.27 to $15.09. Strikes inside that band hold most of the premium and see most of the action.
KURA options chain highlights: open interest, volume and skew
The live KURA options chain shows a put/call open-interest ratio of 8.38 (bearish-leaning (more puts)), with at-the-money implied volatility near 143.6%.
Snapshot of open interest, volume and implied volatility for the nearest scanned expiration — context, not a trading signal.
KURA insider trading activity (SEC Form 4)
Open-market insider transactions at KURA over roughly the last six months, from SEC Form 4 filings. Open-market buys are the rarer, more telling signal — routine selling under pre-arranged plans is common, so read a net-selling figure with that in mind.
| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| Leoni Mollie | Sell | 84,929 | $834K | 2026-06-18 |
| Powl Brian T. | Sell | 10,000 | $110K | 2026-05-21 |
| FORD KATHLEEN | Sell | 2,257 | $20K | 2026-05-19 |
| Powl Brian T. | Sell | 339 | $3K | 2026-05-19 |
| Bair Teresa Brophy | Sell | 2,256 | $21K | 2026-05-18 |
Source: SEC Form 4 filings via Finnhub. Open-market purchases (P) and sales (S) only — grants, option exercises, gifts and tax withholding are excluded. Informational context, not investment advice.
Earnings & IV crush
KURA's next earnings report is due around November 3, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
Key figures
- Market cap
- $822M
- Beta (vs market)
- 0.38
- 52-week range
- $5.45–$12.49 (74% up the range)
- Short interest
- 15.9% of float · 7.7 days to cover
With 15.9% of KURA's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
Other strong setups for KURA
If your view on KURA differs, these also scored well in the latest scan:
How to choose an options strategy for KURA
Start with your outlook on KURA, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while KURA stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →⧉ Embed this free calculator on your site →
How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open KURA in the free calculator →
Frequently asked questions
What is the best options strategy for KURA?
It depends on your outlook. Bullish traders often use a long call or bull call spread on KURA; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are KURA options liquid enough to trade?
Kura Oncology, Inc. (KURA) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade KURA options?
Buying a single KURA call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade KURA or any security. Do your own research.
What does Kura Oncology, Inc. do?
Kura Oncology, Inc. (KURA) operates in the Biotechnology industry. The "About Kura Oncology, Inc." section above gives a fuller picture of what the company does and how it earns money.
Does Kura Oncology, Inc. pay a dividend?
We don't show a confirmed dividend yield for Kura Oncology, Inc. here, so treat it as uncertain: before writing calls, check its current dividend and ex-dividend date with your broker — an approaching ex-dividend date can trigger early assignment on in-the-money short calls.
When does Kura Oncology, Inc. next report earnings?
Kura Oncology, Inc.'s next earnings are expected around November 3, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.
Price trend
Tickers related to KURA
Comparing KURA with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 4930 Directors Place, Suite 500, San Diego, CA, 92121, United States
- Industry
- Biotechnology
- Employees
- 260
- CEO
- Dr. Troy Edward Wilson J.D., Ph.D.
- Phone
- 858 500 8800
- Website
- kuraoncology.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.